<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04753970</url>
  </required_header>
  <id_info>
    <org_study_id>20-000087</org_study_id>
    <nct_id>NCT04753970</nct_id>
  </id_info>
  <brief_title>Retina is a Marker for Cerebrovascular Heath</brief_title>
  <official_title>Retinal Vasoreactivity is a Marker for Cerebral Small Vessel Disease Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cerebral small vessel disease (SVD), present in 80-94% of adults over age 65 years, increases&#xD;
      the risk of stroke by 2-fold, and dementia by 2.3-fold. There is currently no treatment to&#xD;
      slow SVD progression. This study aims to test whether impaired cerebral and retinal&#xD;
      vasoreactivity may serve as biomarker for SVD progression, and to evaluate the safety and&#xD;
      efficacy of cilostazol (antiplatelet agent with vasodilatory and anti-inflammatory&#xD;
      properties) for the treatment of SVD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, observational nested pilot randomized controlled study to discover&#xD;
      retinal biomarkers that would predict cerebral small vessel disease progression, and evaluate&#xD;
      the safety/efficacy of cilostazols in slowing SVD progression. Twenty CADASIL, 40 sWMD, 20&#xD;
      lobar CMB, and 20 age-matched healthy controls from the Mayo Clinic Florida Familial&#xD;
      Cerebrovascular Disease Registry and neurology clinic will be recruited. All participants&#xD;
      will undergo OCTA retinal scan, MRI-BOLD brain scan, cognitive battery evaluation, and blood&#xD;
      sample at baseline and a 12-month follow-up visit. Key outcome measures are: RVR, CVR,&#xD;
      cognition, WMH volume, and CMB volume. The 40 patients diagnosed in the course of routine&#xD;
      clinical care with sWMD will be randomized in 1:1 ratio to receive cilostazol 100mg bid (or&#xD;
      50 mg bid if taking medications known to affect metabolism of cilostazol) or no cilostazol,&#xD;
      and followed for WMD progression, and secondarily for changes in cognition, RVR and CVR. Flow&#xD;
      diagram below outlines the study design. Note that in addition to what is shown in the trial&#xD;
      flow diagram, patients will have telephone visits between baseline and 12 month clinic visits&#xD;
      biweekly for 3 months and then monthly thereafter. These visits will consist of a survey for&#xD;
      adverse events and at the 1-, 3-, 6- and 9-month telephone visits patients will also get a&#xD;
      modified Rankin scale assessment, a Six-item screener (cognitive assessment) and a PHQ-2&#xD;
      (depression screen).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>white matter disease volume</measure>
    <time_frame>1 year</time_frame>
    <description>change in total white matter disease volume</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cognition</measure>
    <time_frame>1 year</time_frame>
    <description>global Z-score and by cognitive domain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke</measure>
    <time_frame>1 year</time_frame>
    <description>ischemic stroke or hemorrhagic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebrovasoreactivity</measure>
    <time_frame>1 year</time_frame>
    <description>change in blood oxygen level dependence (BOLD) per unit of end tidal PCO2 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>retinal vasoreactivity</measure>
    <time_frame>1 year</time_frame>
    <description>change in retinal vessel density pre/post CO2 challenge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cerebral Small Vessel Diseases</condition>
  <condition>Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy</condition>
  <condition>Cerebral Microbleeding</condition>
  <condition>Sporadic White Matter Disease</condition>
  <arm_group>
    <arm_group_label>Cilostazol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cilostazol 100mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol</intervention_name>
    <description>Cilostazol 100mg BID</description>
    <arm_group_label>Cilostazol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥18 yo.&#xD;
&#xD;
          -  Diagnosis of CADASIL, sporadic WMD or lobar CMB and age-matched healthy controls (eg.&#xD;
             patient's spouse or unrelated friends without SVD)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age&lt;18yo&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Breast feeding&#xD;
&#xD;
          -  Unable to follow commands&#xD;
&#xD;
          -  Unable to tolerate MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Lin, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ed Michel, BA</last_name>
    <phone>904-953-4519</phone>
    <email>michel.ed@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meredith McDonald, BA</last_name>
    <phone>904-953-4200</phone>
    <email>mcdonald.meredith@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ed Michel, B.S.</last_name>
      <phone>904-953-4573</phone>
      <email>michel.ed@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Meredith McDonald, B.S.</last_name>
      <phone>9049534200</phone>
      <email>mcdonald.meredith@mayo.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Michelle P. Lin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukoencephalopathies</mesh_term>
    <mesh_term>Cerebral Small Vessel Diseases</mesh_term>
    <mesh_term>CADASIL</mesh_term>
    <mesh_term>Dementia, Multi-Infarct</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

